(Q33390204)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Valeria Romeo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Chiara Gallo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Giuseppe Di Lorenzo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Sabino De Placido

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alfredo Marinelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

17 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

311-319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11060-010-0168-y

5 February 2020

exact match

0 references

cites work

Long-term survival with glioblastoma multiforme

1 reference

12 December 2020

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

1 reference

12 December 2020

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1 reference

12 December 2020

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

1 reference

12 December 2020

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

1 reference

12 December 2020

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

1 reference

12 December 2020

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

12 December 2020

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

12 December 2020

Phase II study of fotemustine in recurrent supratentorial malignant gliomas

1 reference

12 December 2020

The 2007 WHO classification of tumours of the central nervous system

1 reference

12 December 2020

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort

1 reference

12 December 2020

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

1 reference

12 December 2020

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

1 reference

12 December 2020

Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study

1 reference

12 December 2020

Logistic regression model of fotemustine toxicity combining independent phase II studies

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology

1 reference

12 December 2020

MR imaging correlates of survival in patients with high-grade gliomas.

1 reference

12 December 2020

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S11060-010-0168-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20556481%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 February 2020

0 references

1 reference